A good night's sleep does far more than leave you feeling refreshed. It triggers the release of growth hormone, which builds muscle and bone, burns fat, and supports healthy growth. Now, researchers at the University of California, Berkeley have uncovered precisely how the brain controls this process.
Published in the journal Cell, the study identifies the brain circuitry responsible for regulating growth hormone during sleep. The team, led by Professor Yang Dan, discovered a previously unknown feedback system that keeps growth hormone levels in balance — linking the hypothalamus to the locus coeruleus, a brainstem region involved in alertness and cognition.
How it works
The nerve cells coordinating growth hormone release sit deep within the hypothalamus. Two peptide hormones — GHRH (which promotes release) and somatostatin (which suppresses it) — behave differently depending on sleep stage. During REM sleep, both increase, driving growth hormone output. During non-REM deep sleep, somatostatin falls while GHRH rises moderately, creating a distinct regulatory pattern.
As growth hormone accumulates during sleep, it stimulates the locus coeruleus, encouraging wakefulness. But if locus coeruleus activity becomes too high, it unexpectedly promotes sleepiness instead — a self-balancing feedback loop.
"Sleep drives growth hormone release, and growth hormone feeds back to regulate wakefulness," said co-author Daniel Silverman. "This balance is essential for growth, repair and metabolic health."
Why it matters
Because growth hormone influences glucose and fat metabolism, consistently poor sleep increases the risk of obesity, diabetes, and cardiovascular disease. The locus coeruleus is also implicated in neurological disorders — problems here are linked to Alzheimer's, Parkinson's, and depression.
"Understanding this neural circuit could point toward new hormonal therapies to improve sleep quality or restore normal growth hormone balance," Silverman said.
The research, supported by the Howard Hughes Medical Institute and the Pivotal Life Sciences Chancellor's Chair fund, offers a concrete neural target for developing treatments for sleep disorders, metabolic diseases, and neurodegenerative conditions.
